Progresif Musküler Distrofili Olguda Anestezi Yönetimi

Authors

Onur Hanbeyoğlu
https://orcid.org/0000-0001-6898-5625

Synopsis

A 25-year-old female patient with progressive muscular dystrophy (PMD), who had been bedridden for five years, underwent emergency surgery for acute ileus. Having the Limb-Girdle Muscular Dystrophy (LGMD) subtype and a tracheostomy due to respiratory muscle involvement, her neuromuscular condition posed high anesthetic risks, including malignant hyperthermia (MH), rhabdomyolysis, and respiratory failure. Preoperative evaluations found her cardiopulmonary system normal, classifying her as ASA IV, and dantrolene was prepared. Volatile inhalation agents and depolarizing muscle relaxants (succinylcholine), which could trigger MH, were strictly avoided. Total Intravenous Anesthesia (TIVA) using propofol and remifentanil was selected under bispectral index (BIS) monitoring, omitting muscle relaxants due to her existing tracheostomy and high sensitivity. The two-hour exploratory laparoscopy and bridotomy were successfully completed without complications, and the patient was transferred awake to the intensive care unit 15 minutes post-surgery. During the seven-day postoperative ICU follow-up, analgesia was provided with intravenous paracetamol, muscle enzymes and electrolytes were regularly monitored, and the patient was discharged on a home ventilator without developing MH or respiratory complications. Ultimately, TIVA proved to be a safe and effective anesthetic technique for patients with PMD and LGMD.

References

Tunçbay T, Tunçbay E. Musküler Distrofiler: Nöromüsküler Hastalıklar. İzmir, Nobel Tıp Kitabevi, 2004;418-497.

Kanagawa M, Toda T. The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. J Hum Genet 2006;51: 915-926.

Chu ML, Moran E. The limb-girdle muscular dystrophies: is treatment on the horizon? Neurotherapeutics. 2018;15:849–62.

Patel NJ, Van Dyke KW, Espinoza LR. Limb-girdle muscular dystrophy 2B and Miyoshi presentations of Dysferlinopathy. Am J Med Sci. 2017;353(5):484–91.

Bushby KM, Beckmann JS. The limb-girdle muscular dystrophies—proposal for a new nomenclature. Neuromuscul Disord. 1995;5(4):337–43.

Joyce NC, Oskarsson B, Jin LW. Muscle biopsy evaluation in neuromuscular disorders. Phys Med Rehabil Clin N Am. 2012;23(3):609–31.

Barash PG, Cullen BF, Stoelting RK, et al. Clinicial Anesthesia 5th edition. Rare Coexiting Diseas. 2006 by Lippincott Williams&Wilkins. pg:502-29. ISBN 0-7817-5745-2.

Başar H. Pediatrik kas hastalıklarında anestezi. Turkiye Klinikleri J Pediatr Sci 2006;2:90-5.

Şener E.B. Miyastenia Gravis, Miyotoni, Musküler Distrofi, Birinci ve İkinci Motor Nöron Hastalığı ve Yanıklı Hastalarda Kas Gevşetici Kullanımı. Türkiye Klinikleri J Anest Reanim-Special Topics 2011;2:36-46.

Brownell AK. Malignant hyperthermia: Relationship to other diseases. Br J Anaesth 1988;60:303-8.

Rusch D, Happe W, Wulf H. Postoperative nausea and vomiting following stabismus surgery in children. Inhalation anesthesia with sevoflurane-nitrous oxide in comparison with intravenous anesthesia with propofol-remifentanil (German). Anaesthetist 1999; 48(2):80-88.

Sarkılar G, Mermer A, Yücekul M, et al. Anaesthetic management of a child with limb-girdle muscular dystrophy. Turk J Anaesth Reanim. 2014;42:103-5.

Kipri M, Şener M, Çalışkan E, ve ark. Miyotonik Distrofi Tip 1 ve Tip 2’li iki hastada spinal anestezi deneyimlerimiz: olgu sunumu. GKDA Derg. 2015;21:121-4.

Gronert GA, Antognini JF, Pessah IN. Malignant Hyperthermia in: Miller RD Anesthesia 5th edition. NewYork Churchill Livingstone; 2000, pg:1033-19.

Larach Mg, Locallia AR, Allen GC et al. A clinical grading scala to predict malignant hyperthermia suspeptibility. Anesthesiology 1994;80:771-775.

Halliday NJ. Malignant hyperthermia. J Craniofac Surg 2003;14:800-802.

Hopkins PM. Malignant hypertermia: advances in clinical management and diagnosis. Br J Anaesth. 2000;85(1):118-28.

Glahn KPE, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hypertermia crisis: guidelines from the European malignant hypertermia group. Br J Anaesth. 2010;105(4):417-20.

Denborough MA, Forster JF, Lovell RRH, et al. Anaesthetic deaths in a family. Br J Anaesth 1962; 34:395–6.

Cohen IT, Kaplan R. Repeat episodes of severe muscle rigidity in a child receiving sevoflurane. Paediatr Anaesth 2006;16:1077-1079.

Girshin M, Mukherjee J, Clowney R. The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne’s muscular dystrophy. Paediatr Anaesth 2006;16:170-173.

Takahashi H, Shimokowa M, Sha K. Sevoflurane can induce rhabdomyolysis in Duchenne’s muscular dystrophy. Masui 2002;51:190-192.

Straub V, Bushby K. The chilhood limb-girdle muscular dystrophies. Semin Pediatr Neurol. 2006;13:104-14.

Hayes J, Veyckemans F, Bissonnette B. Duchenne muscular dystrophy: an old anesthesia problem revisited. Pediatric Anesthesia 2008;18:100-106.

Marks LF, Edwards JC, Linter SPK. Propofol during cardiopulmonary bypass in a patient susceptible to malignant hyperpyrexia. Anaesth Intensive Care. 1988;16:482–485.

Fruen BR, Michelson JR, Roghair TJ, et al. Effects of propofol on Ca21 regulation by malignant hyperthermia-susceptible muscle membranes. Anesthesiology. 1995;82:1274-1282.

Plotz FB, Waalkens HJ, Verkade HJ, et al. Fatal side effects of continuous propofol infusion in children may be related to malignant hyperthermia. Anaesth Intensive Care. 1996 Dec;24(6):724.

Neff SPW, Futter ME, Anderson BJ. Fatal outcome after propofol sedation in children. Anaesth Intensive Care.1997;25:581-583.

Pollock AN, McKenzie AJ, Hodges M. Propofol and malignant hyperthermia susceptibility. Anaesth Intensive Care. 1997;25:583-585.

Milligan KA. Propofol and dystrophia myotonica. Anaesthesia 1988; 43:513-14.

Published

January 13, 2022

License

License